[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Ming Ju Biotechnology Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100552920",false,"NCT06479356","CD19-targeted CAR T Cells for Relapsed or Refractory (R\u002FR) Large B-cell Lymphoma","An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed or Refractory (R\u002FR) LBCL","Inclusion Criteria:\n\n1. ≥18 years old;\n2. Sign on the informed consent;\n3. Subjects must have histologically confirmed Large B-cell Lymphoma;\n4. Subjects had been treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT);\n5. Subjects have accessible PET-positive lesion and have measurable CT-positive lesion according to Lugano Classification;\n6. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1;\n7. Adequate organ function;\n8. Adequate vascular access for leukapheresis procedure;\n9. Subjects who have previously received CD19 targeted therapy must confirm that lymphoma lesions still express CD19;\n10. Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of Relma-cel;\n11. Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after the last dose of Relma-cel.\n\nExclusion Criteria:\n\n1. Primary CNS lymphoma;\n2. History of another primary malignancy that has not been in remission for at least 2 years;\n3. Subjects has HBV,HCV,HIV or syphilis infection at the time of screening;\n4. Active deep venous thrombosis(DVT)\u002FPulmonary embolism(PE),or active DVT\u002FPE requires anti-coagulation within 3 months prior to signing the ICF;\n5. Subjects with uncontrolled systemic fungal,bacterial,viral or other infection;\n6. Presence of acute or chronic graft-versus-host disease(GVHD);\n7. History of any serious cardiovascular disease or presence of clinically relevant CNS pathology;\n8. Pregnant or nursing woman;\n9. Subjects using of any chemotherapy,corticosteroid,experiment agents,GVHD therapies,radiation,allo-HSCT or any other therapies for lymphoma must go through a specific wash-out period before leukapheresis;\n10. Uncontrolled conditions or unwillingness or inability to follow the procedures required in the protocol;\n11. Received CAR T-cell or other genetically-modified T-cell therapy previously.","ALL","18 Years",{"count":18,"type":19},12,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is an open-label, single-arm study to treat the adult R\u002FR Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.",[25,26],"Non-Hodgkin Lymphoma","Large B-cell Lymphoma",[28,29,30,31,32],"JWCAR029","B-Cell Malignancies","CAR T cells","Chimeric antigen receptor","Relapsed\u002FRefractory","RECRUITING","2024-08-19",{"date":36,"type":37},"2024-08-21","ACTUAL",{"date":39,"type":37},"2024-08-15",{"date":41,"type":19},"2026-12-31",{"name":43,"class":44},"Shanghai Ming Ju Biotechnology Co., Ltd.","INDUSTRY",1,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":5},"100527009","NCT06142188","Relmacabtagene Autoleucel in Hematologic Malignancies","A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel","Inclusion Criteria:\n\n1. Signed informed consent\n2. Patients who have been treated with Relma-cel, including those who have received off-label products;\n3. If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.\n\nExclusion Criteria:\n\n1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.",{"count":53,"type":19},150,"OBSERVATIONAL","To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world",[57,26,58],"Lymphoma, B-Cell","Follicular Lymphoma",[60,61],"Relmacabtagene Autoleucel","Chimeric antigen receptor T cells","NOT_YET_RECRUITING","2023-11-15",{"date":65,"type":37},"2023-11-21",{"date":67,"type":19},"2023-12-28",{"date":69,"type":19},"2038-12-31",{"name":43,"class":44},""]